Moreover, different trials are testing chimeric antigen receptor (CAR) T-cells targeting HER2, such as HER2-specific CAR T-cells in combination with an intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system, including HER2-specific CAR T-cells, react to the tumor (NCT03740256) [66,67]. The gene discussed is ERBB2; the disease is neoplasm.